Lv12
20 积分 2022-11-10 加入
KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema
5小时前
已完结
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema
6小时前
已完结
Efficacy of Intravitreal Injection of Aflibercept in Neovascular Age-Related Macular Degeneration With or Without Choroidal Vascular Hyperpermeability
1个月前
已完结
[Chinese expert consensus on the standardization of OCT and image interpretation and reporting in fundus diseases (2025): a Delphi approach]
1个月前
已完结
Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
1个月前
已完结
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review
1个月前
已完结
Defining response to anti-VEGF therapies in neovascular AMD
1个月前
已完结
Experimental Models in Neovascular Age Related Macular Degeneration
1个月前
已完结
Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration
7个月前
已完结
Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities
8个月前
已完结
皖公网安备34019202002308
